Ideally, a nanomedicine should have an enhanced inhibitory effect on immunosuppressor cells (regulatory T-cells, M2-polarised tumour-associated macrophages, myeloid-derived suppressor cells) and engender higher activation of immune cells that promote antitumour effects (CD8+ T-cells, NK cells). Here, CD8A is linked to neoplasm.